RU2420281C2 - Method of treating diseases caused by herpes virus - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to dermatovenerology and can be used for treatment of diseases caused by herpes virus. For this purpose pharmaceutical composition, containing triiodide of 1,3-diethylbenzimidasolium.

EFFECT: creation of novel method which makes it possible to increase efficiency and reduce cost of treatment of diseases caused by herpes virus.

3 ex

Description

The invention relates to the field of pharmacology, in particular to a method for the treatment of viral diseases caused by the herpes virus.

A known method of treating diseases caused by the herpes virus (herpetic keratitis, herpetic stomatitis, genital herpes) by using the drug "Bonaphton" containing bromnaphthoquinone as the active principle (Pershin G.N., Arievich AM, Bogdanova N.S. et al. The antiviral drug bonafton in the treatment of viral skin diseases // Vesti dermatologii - 1983. - No. 12. - P.50-53).

The lack of analogue should include an insufficiently high level of pharmacological activity.

The closest in effectiveness to the claimed method is the use of the drug "Zovirax" containing as an active principle acyclovir. The cream is used to treat a wide range of infections caused by Herpes simplex and Herpes zoster viruses (Zovirax (acyclovir). Herpesvirus diseases. Wellcome Foundation Ltd Herts.-England, 1983).

The disadvantage of the prototype should include the need for high concentrations of expensive active substance.

The objective of the invention is to expand the arsenal of funds for the treatment of diseases caused by the herpes virus by creating a new highly effective and inexpensive method of treatment.

The technical result in this case is to provide treatment for viral diseases caused by the herpes virus.

The technical result is achieved by a method of treating viral diseases caused by the herpes virus using medicinal compositions containing 1,3-diethylbenzimidazolium triiodide as an active substance.

Obtaining compositions for the implementation of this method containing 1,3-diethylbenzimidazolium triiodide can be carried out as follows. As the active substance of the resulting composition used is 1,3-diethylbenzimidazolium triiodide (Specifications 2492-003-40530251-05 or Pharmacopoeia article 42-0609-6576-05), which determines its qualitative and quantitative composition. In the manufacture of liquid and soft forms of the composition in an organic solvent approved for use in pharmacy, dark brown crystals of 1,3-diethylbenzimidazolium triiodide are dissolved. The pharmacological activity of the resulting composition is not affected by which of the solvents will be used. It is also possible the use of excipients. To obtain ointment forms, the resulting solution is mixed with a hydrophilic or hydrophobic ointment base.

In the manufacture of dry forms of the composition (powders), finely ground crystals of 1,3-diethylbenzimidazolium triiodide are mechanically mixed with white powder of medical low molecular weight polyvinylpyrrolidone and / or with finely divided polyethylene glycol 1500, 3000, 4000 or 6000.

Methods for producing compositions are safe for individuals involved in the process.

Example 1

Polyvinylpyrrolidone low molecular weight medical (M.M. 12600 D) in an amount of 2.0 wt.% Is dissolved at 20-25 ° C in an organic solvent dimexide taken in an amount of 5.0 wt.%. Crystals of 1,3-diethylbenzimidazolium triiodide in the amount of 3.0 wt.% Are dissolved in the resulting solution. The resulting solution is introduced into the molten polyethylene glycol of 1500 - 25.0 wt.% In polyethylene glycol 400 - 65.0 wt.% At a temperature not exceeding 35 ° C and mixed while cooling to a homogeneous state. Get a composition (ointment) with antiviral activity against herpes virus (see table 1).

Example 2

Finely ground crystals of 1,3-diethylbenzimidazolium triiodide in an amount of 4.0 wt.% Are mechanically mixed with low molecular weight medical polyvinylpyrrolidone (M.M. 12600 D) taken in an amount of 6.0 wt.% And finely divided polyethylene glycol 1500, taken in an amount of 90, 0 wt.%. Get a composition (powder) with antiviral activity against herpes virus (see table 1).

Example 3

Fine crystals of 1,3-diethylbenzimidazolium triiodide in an amount of 4.0 wt.% Are mechanically mixed with low molecular weight medical polyvinylpyrrolidone (M.M. 12,600 D) taken in an amount of 16.0 wt.% And dissolved in 95% ethyl alcohol taken in the amount of 80.0 wt.%. Get a composition (oral solution) with antiviral activity against herpes virus (see table 1).

The effect of compositions containing 1,3-diethylbenzimidazolium triiodide on the reproduction of herpes simplex virus.

The compositions (in the form of an ointment, powder or solution) were introduced into the cell culture after adsorption by the cells of the herpes simplex virus (Herpes simplex virus, type 1, strain L ₂ ) of the culture to final concentrations of the active principle - 1,3-diethylbenzimidazolium triiodide from 0.5 to 5.0 mg / ml according to the scheme after 30 minutes and 120 minutes after the introduction of the virus at a dose of 100 TCD ₅₀ . The activity of the drug was studied on a model of two tissue cultures sensitive to the herpes virus: VERO cells and M-22 diploid cells. The results of the study are presented in table 1.

Table 1. Antiviral activity of compositions containing 1,3-diethylbenzimidazolium triiodide The final concentration of 1,3-diethylbenzimidazolium triiodide mg / ml Incubation time in minutes The frequency of the drug The percentage of suppression of viral activity Ointment Powder Solution 5,0 thirty one 45 40 45 thirty 5 fifty fifty fifty 5,0 120 one fifty 45 fifty 120 5 55 55 55 0.5 thirty one twenty fifteen twenty thirty 5 25 25 25 0.5 120 one 35 thirty 35 120 5 35 35 40

Thus, all compositions containing 1,3-diethylbenzimidazolium triiodide as an active substance have pronounced antiherpetic properties when using two cell cultures (VERO cells and diploid cells of the human lung embryo - M-22) and two regimens - 30 and 120 minutes .

A clinical study of the effectiveness of an ointment containing 1,3-diethylbenzimidazolium triiodide in the treatment of labial herpes simplex

The study involved 15 patients with a diagnosis of labial herpes simplex. The diagnosis was made on the basis of patient complaints and a characteristic clinical picture.

An ointment containing 1,3-diethylbenzimidazolium triiodide was applied every 2 hours while awake for 7 days.

The severity of the clinical symptoms of the disease was expressed on a three-point scale.

The results of clinical studies indicate that in the group of patients who received monotherapy with ointment containing 1,3-diethylbenzimidazolium triiodide (table 2), all the symptoms of the disease disappeared on the 4th day of treatment. At the same time, without treatment, the symptoms of the herpes virus disease are noted within 7-8 days.

Table 2. The dynamics of clinical symptoms in a group of patients who received monotherapy with ointment containing 1,3-diethylbenzimidazolium triiodide symptomatology Before treatment 1st day of therapy 2nd day 3rd day 4th day 5th day 6th day 7th day 8th day Itching 2,4 2,3 1.4 0.7 0 0 0 0 0 Burning 1.9 1.7 1,0 0.2 0 0 0 0 0 Bubbles 2.5 2.2 0.8 0.4 0 0 0 0 0 Swelling 2.6 2.6 2.0 0.7 0 0 0 0 0 Hyperemia 2,8 2.6 2.1 1,2 0.5 0 0 0 0

Thus, the antiherpetic properties of a composition containing 1,3-diethylbenzimidazolium triiodide as an active substance are confirmed in a clinical setting.

The described means and methods by which it is possible to implement a method of treating diseases caused by the herpes virus by using compositions containing 1,3-diethylbenzimidazolium triiodide as an active substance, confirm the industrial applicability of the claimed invention.

Claims (1)

A method of treating diseases caused by the herpes virus, which consists in using a pharmaceutical composition containing 1,3-diethylbenzimidazolium triiodide as an active substance.